During the last BIO Asia-Taiwan event HCS Pharma was awarded by the National Health Research Institute (NHRI) as a key company (關鍵新創) in the “Partnering and Medical Innovation” category (攜手同行暨創醫獎) for the BIOMIMESYS® technology. BIOMIMESYS® was recognized as a groundbreaking technology, allowing to reproduce any type of healthy or cancerous organ/tissue ECM thanks to its unique asset combining both behavior (solid scaffold and hydrogel behavior). This unique Hyaluronic Acid-based hydroscaffold is the only one reproducing the porosity, stiffness, composition of in vivo ECM.
We were very happy to be present at BIO Asia-Taiwan from 4 to 7 November as a member of the National Health Research Institutes (NHRI) Technology Transfer & Incubation Center (TTIC). Joseph CHOU, the representative of HCS Pharma Taïwan, and his team have presented our products BIOMIMESYS® and our last developments. They had a lot of visitors interested by our products and many promising contacts were made.
We are really happy for such recognition in Taïwan et we warmly thanks the entire HCS Pharma Taiwan team.